Schizophrenia | Access and Reimbursement | US | 2017
Market Outlook
Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and long-acting depot formulations in the United States. Many of the oral atypical antipsychotic therapies used to treat the symptoms of schizophrenia are generically available, potentially creating barriers to access for branded oral agents (e.g., Sunovion’s Latuda, Otsuka/Lundbeck’s Rexulti, Allergan’s Vraylar). Newer depot formulations of atypical antipsychotics (e.g., Alkermes’s Aristada, Janssen’s Invega Trinza) offer the possibility of better patient compliance, although access to these therapies also may be restricted due to their high cost relative to other agents. With a wide variety of antipsychotic therapy options available, novel oral schizophrenia therapies will be entering a crowded and highly genericized market and may face reimbursement difficulties.
Questions Answered
- How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Latuda, Rexulti, Vraylar) and depot atypical antipsychotics (e.g., Otsuka/Lundbeck’s Abilify Maintena, Janssen’s Risperdal Consta) in this genericized market?
- What do payers report as the coverage status of branded oral and depot atypical antipsychotics on Medicaid and commercial plans? Is automatic generic substitution employed for oral therapies that are generically available?
- What are the preferred pharmacoeconomic models for payers when evaluating new schizophrenia therapies, and what types of pharmacoeconomic data do they find most compelling?
- How do payers anticipate including emerging oral schizophrenia therapies on formularies at various price points, and how do psychiatrists expect to incorporate them in the treatment of schizophrenia patients?
Product Description
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
